These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 30002451)

  • 21. Cancer Immunotherapy: A Simple Guide for Interventional Radiologists of New Therapeutic Approaches.
    Digklia A; Duran R; Homicsko K; Kandalaft LE; Hocquelet A; Orcurto A; Coukos G; Denys A
    Cardiovasc Intervent Radiol; 2019 Sep; 42(9):1221-1229. PubMed ID: 30209564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunological and clinical implications of immune checkpoint blockade in human cancer.
    Kim HD; Park SH
    Arch Pharm Res; 2019 Jul; 42(7):567-581. PubMed ID: 30843144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.
    Cristescu R; Mogg R; Ayers M; Albright A; Murphy E; Yearley J; Sher X; Liu XQ; Lu H; Nebozhyn M; Zhang C; Lunceford JK; Joe A; Cheng J; Webber AL; Ibrahim N; Plimack ER; Ott PA; Seiwert TY; Ribas A; McClanahan TK; Tomassini JE; Loboda A; Kaufman D
    Science; 2018 Oct; 362(6411):. PubMed ID: 30309915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Towards In Silico Prediction of the Immune-Checkpoint Blockade Response.
    Chen K; Ye H; Lu XJ; Sun B; Liu Q
    Trends Pharmacol Sci; 2017 Dec; 38(12):1041-1051. PubMed ID: 29089139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade.
    Wang Z; Zhao J; Wang G; Zhang F; Zhang Z; Zhang F; Zhang Y; Dong H; Zhao X; Duan J; Bai H; Tian Y; Wan R; Han M; Cao Y; Xiong L; Liu L; Wang S; Cai S; Mok TSK; Wang J
    Cancer Res; 2018 Nov; 78(22):6486-6496. PubMed ID: 30171052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers for immune therapy in gastrointestinal cancers.
    Weinberg BA; Hameed R; Marshall JL
    Clin Adv Hematol Oncol; 2019 Feb; 17(2):109-119. PubMed ID: 30845114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Genetic Mutation Accumulation and Clinical Outcome of Immune Checkpoint Blockade Therapy].
    Takahashi M
    Gan To Kagaku Ryoho; 2016 Jun; 43(6):678-82. PubMed ID: 27306805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade.
    Wilkinson RW; Leishman AJ
    Front Immunol; 2018; 9():1082. PubMed ID: 29910800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy.
    Davoli T; Uno H; Wooten EC; Elledge SJ
    Science; 2017 Jan; 355(6322):. PubMed ID: 28104840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.
    Parchment RE; Voth AR; Doroshow JH; Berzofsky JA
    Semin Oncol; 2016 Aug; 43(4):501-13. PubMed ID: 27663482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
    Meng X; Huang Z; Teng F; Xing L; Yu J
    Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomic determinants of cancer immunotherapy.
    Miao D; Van Allen EM
    Curr Opin Immunol; 2016 Aug; 41():32-38. PubMed ID: 27254251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging role of circulating tumor cells in immunotherapy.
    Rzhevskiy A; Kapitannikova A; Malinina P; Volovetsky A; Aboulkheyr Es H; Kulasinghe A; Thiery JP; Maslennikova A; Zvyagin AV; Ebrahimi Warkiani M
    Theranostics; 2021; 11(16):8057-8075. PubMed ID: 34335980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance mechanisms to immune checkpoints blockade by monoclonal antibody drugs in cancer immunotherapy: Focus on myeloma.
    Isazadeh A; Hajazimian S; Garshasbi H; Shadman B; Baghbanzadeh A; Chavoshi R; Taefehshokr S; Farhoudi Sefidan Jadid M; Hajiasgharzadeh K; Baradaran B
    J Cell Physiol; 2021 Feb; 236(2):791-805. PubMed ID: 32592235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy.
    Cabel L; Proudhon C; Romano E; Girard N; Lantz O; Stern MH; Pierga JY; Bidard FC
    Nat Rev Clin Oncol; 2018 Oct; 15(10):639-650. PubMed ID: 30050094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Next generation predictive biomarkers for immune checkpoint inhibition.
    Khagi Y; Kurzrock R; Patel SP
    Cancer Metastasis Rev; 2017 Mar; 36(1):179-190. PubMed ID: 27873079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune checkpoints and cancer in the immunogenomics era.
    Park R; Winnicki M; Liu E; Chu WM
    Brief Funct Genomics; 2019 Mar; 18(2):133-139. PubMed ID: 30137232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy.
    Chang L; Chang M; Chang HM; Chang F
    Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):e15-e21. PubMed ID: 28877075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune checkpoint signaling and cancer immunotherapy.
    He X; Xu C
    Cell Res; 2020 Aug; 30(8):660-669. PubMed ID: 32467592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.